A phase 1a/b dose escalation study of the mutation agnostic FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia Meeting Abstract
| Authors: | Goldberg, A. D.; Ohanian, M.; Koller, P.; Altman, J. K.; Cherry, M.; Tomlinson, B.; Chandhok, N.; Zhang, H.; Rastgoo, N.; Benbatoul, K.; Jin, Y.; Su, G.; Marango, J.; Howell, S. B.; Rice, W. G.; Bejar, R. |
| Abstract Title: | A phase 1a/b dose escalation study of the mutation agnostic FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia |
| Meeting Title: | 63nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398805004 |
| DOI: | 10.1182/blood-2021-149333 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1272 -- Hybrid meeting, also took place online -- Source: Wos |
